Related Experiment Video
Updated: Jan 20, 2026

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
Published on: September 11, 2015
[Immunotherapy in Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer]
1Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Abstract:
Targeted therapy and immunotherapy are important treatments for non-small cell lung cancer (NSCLC). At present, the clinical and basic research of epidermal growth factor receptor (EGFR) mutation NSCLC is still in the exploratory stage, needing to optimize the efficacy, combination, sequence and dosage of immunotherapy and other treatments, to clarify the relationship between EGFR mutation, immune microenvironment and the efficacy of immunotherapy. In this review, we summarized the newly updated data about immunotherapy in EGFR mutant NSCLC in term of pre-clinical study, programmed cell death protein ligand 1 (PD-L1) expression, tumor mutation burden and treatment. .
Insights
Immunotherapy shows promise for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Further research is needed to optimize treatments and understand the interplay between EGFR mutations, the tumor microenvironment, and immunotherapy response.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) treatment increasingly involves targeted therapy and immunotherapy.
- Epidermal growth factor receptor (EGFR) mutations are a key focus in NSCLC research.
- Current understanding of immunotherapy in EGFR-mutant NSCLC requires further development.
Purpose of the Study:
- To review updated data on immunotherapy for EGFR-mutant NSCLC.
- To explore the relationship between EGFR mutations, immune microenvironment, and treatment efficacy.
- To identify areas for optimizing immunotherapy combinations, sequencing, and dosage.
Main Methods:
- Comprehensive literature review of recent preclinical and clinical studies.
- Analysis of data concerning programmed cell death protein 1 ligand 1 (PD-L1) expression.
- Evaluation of tumor mutation burden (TMB) in relation to immunotherapy outcomes.
Main Results:
- Emerging data suggests potential roles for immunotherapy in EGFR-mutant NSCLC.
- PD-L1 expression and TMB are critical factors influencing treatment response.
- Optimization of treatment strategies is essential for improving efficacy.
Conclusions:
- Immunotherapy represents a developing frontier for EGFR-mutant NSCLC.
- Clarifying the tumor immune microenvironment is crucial for personalized treatment.
- Continued research is vital to refine treatment protocols and enhance patient outcomes.
More Related Videos
Related Concept Videos
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: Osmolarity
Tumor Immunotherapy
Renewal of Skin Epidermal Stem Cells

